Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junya Kuroda

Showing results (1-10 of 351) with videos related to

Pageof 36
Sort By:
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 10, 2014
[Current status of clinical trials of novel agents for multiple myeloma]Junya Kuroda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2017
Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practiceJunya Kuroda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2012
[Trends in development of novel therapeutic agents for multiple myeloma]Junya Kuroda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 1, 2014
[Future therapeutic strategy for multiple myeloma through the targeting of cell signaling pathways]Junya Kuroda
Circulation Journal : Official Journal of the Japanese Circulation Society|April 3, 2018
Detrimental Effects of Insufficient Warfarin Therapy　- A Warning Against Imprudent Use of Warfarin for Atrial Fibrillation PatientsJunya Kuroda
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2015
[Therapeutic monoclonal antibodies against multiple myeloma]Junya Kuroda
Journal of Cardiovascular Translational Research|June 19, 2010
NADPH oxidase and cardiac failureJunya Kuroda, Junichi Sadoshima
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|August 10, 2004
[Cell therapy. 1. Donor lymphocyte infusion therapy]Junya Kuroda, Shinya Kimura
Critical Reviews in Oncology/Hematology|November 22, 2008
Involvement of BH3-only proteins in hematologic malignanciesJunya Kuroda, Masafumi Taniwaki
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 15, 2020
[Ⅲ.Therapeutic Strategy for Relapsed/Refractory Multiple Myeloma-The Logic and Practice]Junya Kuroda, Yuji Shimura
Pageof 36

Showing results (1-10 of 351) with videos related to

Sort By:
Pageof 36
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 10, 2014
[Current status of clinical trials of novel agents for multiple myeloma]Junya Kuroda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2017
Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practiceJunya Kuroda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2012
[Trends in development of novel therapeutic agents for multiple myeloma]Junya Kuroda
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 1, 2014
[Future therapeutic strategy for multiple myeloma through the targeting of cell signaling pathways]Junya Kuroda
Circulation Journal : Official Journal of the Japanese Circulation Society|April 3, 2018
Detrimental Effects of Insufficient Warfarin Therapy　- A Warning Against Imprudent Use of Warfarin for Atrial Fibrillation PatientsJunya Kuroda
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2015
[Therapeutic monoclonal antibodies against multiple myeloma]Junya Kuroda
Journal of Cardiovascular Translational Research|June 19, 2010
NADPH oxidase and cardiac failureJunya Kuroda, Junichi Sadoshima
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|August 10, 2004
[Cell therapy. 1. Donor lymphocyte infusion therapy]Junya Kuroda, Shinya Kimura
Critical Reviews in Oncology/Hematology|November 22, 2008
Involvement of BH3-only proteins in hematologic malignanciesJunya Kuroda, Masafumi Taniwaki
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 15, 2020
[Ⅲ.Therapeutic Strategy for Relapsed/Refractory Multiple Myeloma-The Logic and Practice]Junya Kuroda, Yuji Shimura
Pageof 36